28th International Conference on
CANCER RESEARCH AND ANTICANCER THERAPIES
International Conference on &
ONCOGENESIS & ONCOLOGIC EMERGENCY MEDICINE
3rd International Conference on &
TUMOR & CANCER IMMUNOLOGY AND IMMUNOTHERAPY
September 17-18, 2018 | San Diego, USA

Ganplex™ and Kimera-Test™: Biotechnological screening tools designed identify human cancer-related virus and SNPs in non-invasive samples

Meda-Monzón E[1]., Delgado Pastelín L[1]., Flores-Fortis M[1]., Flores-Bahena C[1]., Medina-García CV[1]., Medina-Soriano S[1]., Zepeda-Hernández R[2]., Gutiérrez-Ospina, G[3] and G. Aguirre[1]

[1]Laboratorio de Innovación en Diagnóstico Molecular, Hakken Enterprise S.A. de C.V., México

[2]Centro de Investigaciones Biomédicas, Universidad de Veracruz, México

[3]Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México, México

Most efforts of allopathic medicine are directed to treat diseases. This path has proved to be costly when chronic diseases, such as cancer and its associated viral co-morbidities, need to be treated and monitored in the long term. Hence, the development of prevention-oriented medicine may reduce the magnitude of the financial burden associated with practicing remedy-based medicine. Ganplex™ and Kimera-Test™, the prime products of Hakken Enterprise, were then conceived to identify individuals with high genetic risk of developing cancer before the disease becomes symptomatic. Ganplex™ and Kimera-Test™ take advantage of DNA extracted from saliva and urine samples to identify cancer-related viruses and SNPs through multiplex assays in a single reaction. At current stage of development, both assays identify cancer related SNPs and the viral sequences with a sensitivity, specificity, and confidence higher than those reported for Sanger's sequencing. Both assays require small DNA quantities to begin with and no purification of PCR products prior hybridization. This shortens to approximately 7 hours the time to provide a result. Hence, Ganplex™ and Kimera-Test™ are biotechnological tools that provide the genetic information needed to identify individuals under risk of developing cancer, a circumstance that would help in personalizing cancer preventing protocols and introducing precision medicine into everyday's life.

Biography

Meda-Monzón E (MSc in Health Sciences), Biotechnology specialist, with a great passion for innovation. MSc Elizabeth has demonstrated ability to turn a promising concept into a world class product by implementing cutting edge technology. During the last four years, she has dedicated her talent and energy to the development of technologies for affordable *in vitro* diagnostics tools for HPV and cancer genetic propensity detection.

elizabeth_meda@hotmail.com

Notes: